Strong prognostic impact of tumor-associated urokinase-type plasminogen activator in completely resected adenocarcinoma of the esophagus

Clinical Cancer Research

Volumn 4, Issue 7, 1998, Pages 1755-1763

  Nekarda, Hjalmar ^a   Schlegel, Petra ^a   Schmitt, Manfred ^a   Stark, Monika ^a   Mueller, James D ^a   Fink, Ulli ^a   Siewert, J Rüdiger ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

UROKINASE;

ADENOCARCINOMA; ADULT; ARTICLE; CANCER INVASION; CANCER STAGING; CANCER SURVIVAL; DISEASE ASSOCIATION; ESOPHAGUS CANCER; HISTOPATHOLOGY; HUMAN; LYMPH NODE METASTASIS; LYMPHATIC SYSTEM; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; RISK ASSESSMENT;

ADENOCARCINOMA; ADULT; AGED; ANALYSIS OF VARIANCE; ESOPHAGEAL NEOPLASMS; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASM PROTEINS; NEOPLASM STAGING; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROGNOSIS; REFERENCE VALUES; SURVIVAL ANALYSIS; URINARY PLASMINOGEN ACTIVATOR;

EID: 0031776764     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (50)

1. Blot, W., Devesa, S. S., Kneller, R. W., and Fraumeni, J. F. Rising incidence of adenocarcinoma of the esophagus and gastric cardia. J. Am. Med. Assoc., 265: 1287-1289, 1991.
2. Nishimaki, T., Holscher, A. H., Schüler, M., Bollschweiler, E., Becker, K., and Siewert, J. R. Histopathological characteristics of early adenocarcinoma in Barrett's esophagus. Cancer (Phila.), 68: 1731-1736, 1991.
3. Thompson, W. M. Esophageal cancer. Int. J. Radiat. Oncol. Biol. Phys., 9: 1533-1565, 1983.
4. Hölscher, A. H., Bollschweiler, E., Schneider, P. M., and Siewert, J. R. Prognosis of early esophageal cancer. Comparison between adeno- and squamous cell carcinoma. Cancer (Phila.), 76: 178-186, 1995.
5. Mahoney, J. L., and Condon, R. E. Adenocarcinoma of the esophagus. Ann. Surg., 205: 557-562, 1987.
6. Blomjous, J. G., Hop, W. C., Langenhorst, B. L., Ten, K. F., Eykenboom, W. M., and Tilanus, H. W. Adenocarcinoma of the gastric cardia. Recurrence and survival after resection. Cancer (Phila.), 70: 569-574, 1992.
7. Liotta, L., Steeg, P. S., and Stetler-Stevenson, W. G. Cancer metastasis and angiogenesis: an imbalance of positive and negative regulation. Cell, 64: 327-336, 1991.
8. Hart, I.R., and Saini, A. Biology of tumor metastasis. Lancet, 339: 1453-1457, 1992.
9. Forst, P., and Levin, B. Clinical implications of the metastatic process. Lancet, 339: 1458-1461, 1992.
10. Zacharski, L. R., Wojtukiewicz, M. Z., Constantini, V., Ornstein, D. L., and Memoli, V. A. Pathways of coagulation/fibrinolysis activation in malignancy. Semin. Thromb. Hemostasis, 18: 104-116, 1992.
11. Duffy, M. J., Reilley, D., O'Sullivan, C., O'Higgins, N., Fenelly, J. N., and Andreasen, P. Urokinase-plasminogen activator, a new and independent prognostic marker in breast cancer. Cancer Res. 50: 6827-6829, 1990.
12. Foekens, J. A., Schmitt, M., van Putten, W. L. J., Peters, H. A., Bontenbal, M., Jänicke, F., and Klijn, J. G. M. Prognostic value of urokinase-type plasminogen activator in 671 primary breast cancer patients. Cancer Res., 52: 6101-6105, 1992.
13. Jänicke, F., Pache, L., Schmitt, M., Ulm, K., Thomssen, C. H., Prechtl, A., and Graeff, H. Both the cytosols and detergent extracts of breast cancer tissues are suited to evaluate the prognostic impact of the urokinase-type plasminogen activator and its inhibitor, plasminogen activator inhibitor type 1. Cancer Res., 54: 2527-2530, 1994.
14. Jänicke, F., Schmitt, M., Pache, L., Ulm, K., Harbeck, N., Höfler, H., and Graeff, H. Urokinase (uPA) and its inhibitor PAI-1 are strong and independent prognostic factors in node-negative breast cancer. Breast Cancer Res. Treat., 24: 195-208, 1993.
15. Nekarda, H., Schmitt, M., Ulm, K., Wenninger, A., Vogelsang, H., Becker, K., Roder, J. D., Fink, U., and Siewert, J.R. Prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in completely resected gastric cancer. Cancer Res., 54: 2900-2907, 1994.
16. Heiss, M. M., Babic, R., Allgayer, H., Gruetzner, K. U., Jauch, K., Loehrs, U., and Schildberg, F. W. Tumor-associated proteolysis and prognosis: new functional risk factors in gastric cancer defined by the urokinase-type plasminogen activator system. J. Clin. Oncol., 13: 2084-2093, 1995.
17. Verspaget, H. W., Sier, C. F., Ganesh, S., Griffioen, G., and Lamers, C. B. Prognostic value of plasminogen activators and their inhibitors in colorectal cancer. Eur. J. Cancer, 31A: 1105-1109, 1995.
18. Ninshino, N., Aoki, K., Tokura, Y., Sakaguchi, S., Takada, Y., and Takada, A. The urokinase type of plasminogen activator in cancer of the digestive tracts. Thromb. Res., 50: 527-535, 1988.
19. Sier, C. F. M., Verspaget, H. W., Griffioen, G., Ganesh, S., Vloedgraven, H. J. M., and Lamers, C. B. H. Plasminogen activators in normal tissue and carcinomas of the human oesophagus and stomach. Gut, 34: 80-85, 1993.
20. Hewin, D. F., Savage, P. B., Alderson, D., and Vipond, M. N. Plaminogen activators in oesophageal carcinoma. Br. J. Surg., 83: 1152-1155, 1996.
21. Hölscher, A. H., Bollschweiler, E., Bumm, R., Bartels, H., Hofler, H., and Siewert, J. R. Prognostic factors of resected adenocarcinoma of the esophagus. Surgery (St. Louis), 118: 845-855, 1995.
22. Siewert, J. R., and Stein, H. Carcinoma of the cardia: carcinoma of the gastroesophageal junction-classification: pathology and extent of resection. Dis. Esophagus, 9: 173-182, 1996.
23. UICC. TNM Atlas: An Illustrated Guide to the TNM/pTNM Classification of Malignant Tumors. Heidelberg, Germany: Springer-Verlag, 1992.
24. WHO. WHO Histological Typing of Esophageal and Gastric Tumors, pp. 20-26. Geneva: WHO, 1990.
25. Laurén, P. The two histological main types of gastric carcinoma: diffuse and so-called intestinal-type carcinoma. Acta Pathol. Microbiol. Scand., 64: 31-49, 1965.
26. Schmitt, M., Jänicke, F., and Graeff, H. Tumor-associated fibrinolysis: the prognostic relevance of plasminogen activators uPA and tPA in human breast cancer. Blood Coagul. Fibrinolysis, 1: 695-702, 1990.
27. Smith, P., Krohn, R. I., Hermanson, G. T., Mallia, A. K., Gartner, F. H., Provenzano, M. D., Fujimoto, E. K., Goeke, N. M., Olson, B. J., and Klenk, D. C. Measurement of protein using bicinchoninic acid. Anal. Biochem., 150: 76-85, 1985.
28. Cox, D. Regression models and life-tables. J. R. Stat. Soc., 34: 187-220, 1972.
29. Segal, M. R. Regression trees for censored data. Biometrics, 44: 35-47, 1988.
30. Breimann, L., Friedmann, J., Ohlsen, R., and Stone, C. Classification and regression trees (CART). Belmont, CA: Wadsworth International Group, 1984.
31. Kaplan, E., and Meier, P. Nonparametric estimation from incomplete observations. J. Am. Stat. Assoc., 53: 457-481, 1958.
32. Nakamura, T., Nekarda, H., Hölscher, A., Bollschweiler, E., Harbec, N., Becker, K., and Siewert, J. R. Prognostic value of DNA ploidy and c-erbB-2 oncoprotein overexpression in adenocarcinoma of Barrett's esophagus. Cancer (Phila.), 73: 1785-1794, 1994.
33. Menke, P. M., Hop, W. C., Mulder, A. H., and Tilanus, H. W. DNA ploidy as a prognostic factor for patients with an adenocarcinoma in Barrett's esophagus. Hepatogastroenterology, 42: 786-788, 1995.
34. Sauter, E. R. Coia, L. R., Eisenberg, B. L., and Hanks, G. E. Transforming growth factor α expression as a potential survival prognosticator in patients with esophageal adenocarcinoma receiving high-dose radiation and chemotherapy. Int. J. Radiat. Oncol. Biol. Phys., 31: 567-569, 1995.
35. Yacoub, L., Goldman, H., and Odze, R. D. Transforming growth factor-α, epidermal growth factor receptor, and MiB-1 expression in Barrett's-associated neoplasia: correlation with prognosis. Mod. Pathol., 10: 105-112, 1997.
36. Duhaylongsod, F. G., Gottfried, M. R., Iglehart, J. D., Vaughn, A. L., and Wolfe, W. G. The significance of c-erb B-2 and p53 immunoreactivity in patients with adenocarcinoma of the esophagus. Ann. Surg., 221: 677-683, 1995.
37. Flejou, J. F., Paraf, F., Muzeau, F., Fekete, D., Henin, S. J., and Potet, F. Expression of c-erbB-2 oncogene product in Barrett's adenocarcinoma: pathological and prognostic correlations. J. Clin. Pathol., 47: 23-26, 1994.
38. Krishnadath, K. K., Tilanus, H. W., van Blankenstein, B. M., Hop, W. C., Kremers, E. D., Dinjens, W. N., and Bosman, F. T. Reduced expression of the cadherin-catenin complex in oesophageal adenocarcinoma correlates with poor prognosis. J. Pathol., 182: 331-338, 1997.
39. Schmitt, M., Harbeck, N., Thomssen, C., Wilhelm, O., Magdolen, V., Reuning, U., Ulm, K., Höfler, H., Jänicke, F., and Graeff, H. Clinical impact of the plasminogen activation system in tumor invasion and metastasis: prognostic relevance and target for therapy. Thromb. Hemostasis, 78: 285-296, 1997.
40. Duffy, M. J. Proteases as prognostic markers. Clin. Cancer Res., 2: 613-618, 1996.
41. Conesi, M., and Blasi, F. Urokinase/urokinase receptor system: internalization/degradation of urokinase-serpin complexes: mechanism and regulation. Biol. Chem. Hoppe-Seyler, 376: 143-155, 1995.
42. Lui, G., Shuman, M. A., and Cohen, R. L. Co-expression of urokinase, urokinase receptor and PAI-1 is necessary for optimum invasiveness of cultured lung cancer cells. Int. J. Cancer, 60: 501-506, 1995.
43. Jänicke, F., Schmitt, M., and Graeff, H. Clinical relevance of urokinase-type and tissue-type plasminogen activators and inhibitor PAI-1 in breast cancer. Semin. Thromb. Hemostasis, 17: 303-312, 1991.
44. Haggitt, R. C., Reid, B. J., Rabinovitch, P. S., and Rubin, C. E. Barrett's esophagus. Correlation between mucin histochemistry, flow cytometry, and histological diagnosis for predicting increased cancer risk. Am. J. Pathol., 131: 53-61, 1988.
45. Kalish, R. J., Clancy, P. E., Orringer, M. B., and Appelman, H. D. Clinical, epidemiological, and morphological comparison between adenocarcinomas arising in Barrett's esophageal mucosa and in the gastric cardia. Gastroenterology, 86: 461-467, 1984.
46. Tahara, E. Molecular biology of gastric cancer. World J. Surg., 19: 484-488, 1995.
47. Sugano, H., Nakamura, K., and Kato, Y. Pathological studies of human gastric cancer. Acta Pathol. Jpn., 32: 329-347, 1982.
48. Lieberman, M. D., Shriver, C. D., Bleckner, S., and Burt, M. Carcinoma of the esophagus. Prognostic significance of histological type. J. Thorac. Cardiovasc. Surg., 109: 130-138, 1995.
49. Gordon, L., and Olshen, R. A. Tree-structured survival analysis. Cancer Treat. Rep., 69: 1065-1069, 1985.
50. Schmitt, M., Thomssen, C., Ulm, K., Seiderer, A., Harbeck, N., Höfler, H., Jänicke, F., and Graeff, H. Time-varying prognostic impact of tumor biological factors urokinase (uPA), PAI-1 and steroid hormone receptor status in primary breast cancer. Br. J. Cancer, 76: 306-311, 1997.